UNSPSC 51111745: Gemtuzumab

This classification denotes an anti-cd33 immunotoxin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8GZG754X6M. European Medicines Agency schedules Gemtuzumab ozogamicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20794. Gemtuzumab generally arises in the molecular formula C73H96IN6O25S3. The term GEMTUZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45.) Most nations schedule Gemtuzumab under HS 30021091 and SITC 54163.

SMILES:. As of Q4 2014, GEMTUZUMAB remains the US FDA Preferred Term for this commodity..

UNSPSC 51111745 Gemtuzumab is a Commodity code for a specific monoclonal antibody pharmaceutical product, yet the recent state and local opportunities tagged under this code do not reflect procurement of gemtuzumab itself. Instead, the posted solicitations show state and local governments buying naloxone (an opioid antagonist), doxycycline and ciprofloxacin (broad-spectrum antibiotics), and drug deactivation systems through piggyback contracts and competitive bidding. The mismatch between the code's nominal scope and the work actually being solicited suggests either a tagging error in the underlying opportunity records or a misalignment between UNSPSC classification and the actual pharmaceutical products state and local procurement offices are acquiring. When state and local governments do procure specialty pharmaceuticals at the commodity level, they typically do so through established cooperative purchasing vehicles such as MMCAP or through direct IFB processes with fixed terms and renewal options, requiring vendors to meet drug-free workplace certification, E-Verify compliance, and specified insurance coverage.

The Illinois Department of Public Health awarded a piggyback pharmaceutical contract in August 2026 to Chartwell Rx LLC for antibiotic supply ($2.99 million over three years with 12-month initial term and renewal options), while Seminole County, Florida posted an IFB in June 2026 for annual naloxone and drug deactivation system procurement (1,900 units of naloxone and 800 deactivation systems annually, quarterly deliveries to Sanford). Recent activity appears concentrated in Florida and Illinois; both solicitations emphasize vendor compliance with federal and state requirements, insurance thresholds, and in the Seminole County case, potential FEMA funding. Given the commodity code's specificity to gemtuzumab—a cancer therapeutic with limited state and local procurement footprint compared to naloxone or broad-spectrum antibiotics—the actual buying activity under this UNSPSC number does not yet support a pursuit strategy based on gemtuzumab supply.